[{"address1": "3020 Carrington Mill Blvd.", "address2": "Suite 475", "city": "Morrisville", "state": "NC", "zip": "27560", "country": "United States", "phone": "212 554 4484", "fax": "212 554 4531", "website": "https://www.tgtherapeutics.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults. The company's development pipeline comprises Umbralisib, an oral inhibitor of PI3K-delta inhibitor for the treatment of adult patients with relapsed or refractory marginal zone lymphoma and follicular lymphoma; TG-1701 is an orally available and covalently bound Bruton's tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK in vitro kinase screening; and TG-1801, a bispecific CD47 and CD19 antibody. Its research pipeline includes various investigational medicines. The company has license agreements with LFB Biotechnologies S.A.S; GTC Biotherapeutics; LFB/GTC LLC; Ildong Pharmaceutical Co. Ltd.; Rhizen Pharmaceuticals, S A. for the development and commercialization of umbralisib; Jiangsu Hengrui Medicine Co.; and Novimmune SA, as well as collaboration agreement with Checkpoint Therapeutics, Inc. for the development and commercialization of anti-PD-L1 and anti-GITR antibody research programs in the field of hematological malignancies. TG Therapeutics, Inc. was incorporated in 1993 and is based in Morrisville, North Carolina.", "fullTimeEmployees": 319, "companyOfficers": [{"maxAge": 1, "name": "Mr. Michael S. Weiss Esq.", "age": 58, "title": "Chairman, CEO & President", "yearBorn": 1966, "fiscalYear": 2023, "totalPay": 1968759, "exercisedValue": 0, "unexercisedValue": 5090000}, {"maxAge": 1, "name": "Mr. Sean A. Power CPA", "age": 42, "title": "CFO, Corporate Secretary & Treasurer", "yearBorn": 1982, "fiscalYear": 2023, "totalPay": 670578, "exercisedValue": 0, "unexercisedValue": 3031375}, {"maxAge": 1, "name": "Ms. Jenna  Bosco", "title": "Senior Vice President of Corporate Communications", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Adam  Waldman", "title": "Chief Commercialization Officer", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}], "auditRisk": 9, "boardRisk": 10, "compensationRisk": 10, "shareHolderRightsRisk": 3, "overallRisk": 10, "governanceEpochDate": 1738368000, "compensationAsOfEpochDate": 1703980800, "executiveTeam": [], "maxAge": 86400, "priceHint": 2, "previousClose": 28.53, "open": 28.3, "dayLow": 28.17, "dayHigh": 30.36, "regularMarketPreviousClose": 28.53, "regularMarketOpen": 28.3, "regularMarketDayLow": 28.17, "regularMarketDayHigh": 30.36, "payoutRatio": 0.0, "beta": 2.26, "forwardPE": 31.020618, "volume": 2405921, "regularMarketVolume": 2405921, "averageVolume": 2092078, "averageVolume10days": 1755480, "averageDailyVolume10Day": 1755480, "bid": 25.98, "ask": 34.32, "bidSize": 1, "askSize": 1, "marketCap": 4683959808, "fiftyTwoWeekLow": 12.93, "fiftyTwoWeekHigh": 36.84, "priceToSalesTrailing12Months": 17.689339, "fiftyDayAverage": 30.967, "twoHundredDayAverage": 24.941774, "trailingAnnualDividendRate": 0.0, "trailingAnnualDividendYield": 0.0, "currency": "USD", "tradeable": false, "enterpriseValue": 4231263744, "profitMargins": -0.054250002, "floatShares": 132762562, "sharesOutstanding": 155664992, "sharesShort": 25744460, "sharesShortPriorMonth": 27632271, "sharesShortPreviousMonthDate": 1736899200, "dateShortInterest": 1739491200, "sharesPercentSharesOut": 0.16540001, "heldPercentInsiders": 0.098129995, "heldPercentInstitutions": 0.63439, "shortRatio": 12.65, "shortPercentOfFloat": 0.18270001, "impliedSharesOutstanding": 155664992, "bookValue": 1.338, "priceToBook": 22.488789, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1727654400, "earningsQuarterlyGrowth": -0.966, "netIncomeToCommon": -14364000, "trailingEps": -0.1, "forwardEps": 0.97, "lastSplitFactor": "100:5625", "lastSplitDate": 1335744000, "enterpriseToRevenue": 15.98, "enterpriseToEbitda": -10370.745, "52WeekChange": 0.68382764, "SandP52WeekChange": 0.16050637, "quoteType": "EQUITY", "currentPrice": 30.09, "targetHighPrice": 55.0, "targetLowPrice": 10.0, "targetMeanPrice": 40.33333, "targetMedianPrice": 44.5, "recommendationMean": 1.625, "recommendationKey": "buy", "numberOfAnalystOpinions": 6, "totalCash": 341040992, "totalCashPerShare": 2.376, "ebitda": -408000, "totalDebt": 253808000, "quickRatio": 3.651, "currentRatio": 4.588, "totalRevenue": 264790000, "debtToEquity": 132.084, "revenuePerShare": 1.829, "returnOnAssets": -0.00068999996, "returnOnEquity": -0.08049, "grossProfits": 233848992, "freeCashflow": -45062376, "operatingCashflow": -28086000, "earningsGrowth": -0.973, "revenueGrowth": -0.494, "grossMargins": 0.88315004, "ebitdaMargins": -0.00154, "operatingMargins": 0.14824, "financialCurrency": "USD", "symbol": "TGTX", "language": "en-US", "region": "US", "typeDisp": "Equity", "quoteSourceName": "Nasdaq Real Time Price", "triggerable": true, "customPriceAlertConfidence": "HIGH", "marketState": "CLOSED", "shortName": "TG Therapeutics, Inc.", "longName": "TG Therapeutics, Inc.", "exchange": "NCM", "messageBoardId": "finmb_143627354", "exchangeTimezoneName": "America/New_York", "exchangeTimezoneShortName": "EST", "gmtOffSetMilliseconds": -18000000, "market": "us_market", "esgPopulated": false, "corporateActions": [], "postMarketTime": 1740790682, "regularMarketTime": 1740776400, "regularMarketChangePercent": 5.4679265, "regularMarketPrice": 30.09, "hasPrePostMarketData": true, "firstTradeDateMilliseconds": 1272893400000, "postMarketChangePercent": 0.0664688, "postMarketPrice": 30.11, "postMarketChange": 0.0200005, "regularMarketChange": 1.5599995, "regularMarketDayRange": "28.17 - 30.36", "fullExchangeName": "NasdaqCM", "averageDailyVolume3Month": 2092078, "fiftyTwoWeekLowChange": 17.16, "fiftyTwoWeekLowChangePercent": 1.3271462, "fiftyTwoWeekRange": "12.93 - 36.84", "fiftyTwoWeekHighChange": -6.75, "fiftyTwoWeekHighChangePercent": -0.18322475, "fiftyTwoWeekChangePercent": 68.38277, "earningsTimestamp": 1741008600, "earningsTimestampStart": 1741008600, "earningsTimestampEnd": 1741008600, "earningsCallTimestampStart": 1741008600, "earningsCallTimestampEnd": 1741008600, "isEarningsDateEstimate": false, "epsTrailingTwelveMonths": -0.1, "epsForward": 0.97, "epsCurrentYear": 0.16148, "priceEpsCurrentYear": 186.33887, "fiftyDayAverageChange": -0.8769989, "fiftyDayAverageChangePercent": -0.028320435, "twoHundredDayAverageChange": 5.148226, "twoHundredDayAverageChangePercent": 0.20640977, "sourceInterval": 15, "exchangeDataDelayedBy": 0, "averageAnalystRating": "1.6 - Buy", "cryptoTradeable": false, "displayName": "TG Therapeutics", "trailingPegRatio": null, "__fetch_time": "2025-03-01"}]